ReviewFrontiers in oncology2025
Research on the function of GPX4 in tumor-targeted treatment based on its molecular structure and features.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Impact of Selenium Exposure During Pregnancy on Risk for Miscarriage: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Lycium barbarum polysaccharides alleviate PVC microplastic-induced ferroptosis and fibrosis in duck kidneys by attenuating NCOA4-mediated ferritinophagy: an in vivo study.Poultry science · 2026Article
- Review
- Decoding the spatiotemporal characteristics of ferroptosis: reshaping tumour therapeutic strategies.Experimental hematology & oncology · 2026Review
- Ferroptosis-induced immune modulation: a new frontier in glioblastoma therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- GPX4 Defines an Immune-Cold Phenotype and Poor Prognosis in Resected Lung Adenocarcinoma.Oncology research · 2026Article
- Protein Post-Translational Modifications in the Regulation of Ferroptosis: New Opportunities and Challenges for Cancer Immunotherapy.International journal of biological sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GPX4 is the only antioxidant enzyme in mammals that can convert cholesterol and phospholipid hydroperoxide into phosphatidylol and cholesterol. Its peculiar molecular structure allows it to perform a variety of biological functions, including oxidative stress, ferroptosis regulation, brain development stimulation, and immune responses. In recent years, several studies have demonstrated that increased GPX4 expression is linked to tumor cell proliferation, growth, migration, and differentiation. Overexpression of GPX4 has been linked to chemoresistance and a poor prognosis in cancers including nasopharyngeal carcinoma, breast cancer, and lung cancer. GPX4 inhibitors have been demonstrated to be effective in the treatment of numerous drug-resistant malignancies. Some tumors, such as glioblastoma, do not react well to single-agent GPX4 inhibitors. Therefore, future research should focus on identifying cancers that are more responsive to GPX4 inhibitors and enhancing the efficacy of these inhibitors. This research investigates the regulatory mechanisms and properties of GPX4 in various tumor cell types, as well as its molecular structure and biological roles, hoping to propose more effective tumor-targeted therapy alternatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.